Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HB-MSC1 is an investigational allogeneic mesenchymal stem cell (MSC) therapy derived from umbilical cord tissue, currently under development by the Centre Hospitalier Universitaire (CHU) de Reims. It is specifically designed for the treatment of critical limb ischemia (CLI) in patients with atheromatous arteriopathy who are undergoing revascularization. The therapy involves the intramuscular administration of 60 to 120 million cells into the affected limb shortly after the surgical or endovascular procedure. HB-MSC1 is hypothesized to enhance the outcomes of revascularization by promoting angiogenesis, modulating the local inflammatory environment, and facilitating tissue repair through the secretion of various growth factors and cytokines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HB-MSC1.